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INTRODUCTION
An acute spinal cord injury (SCI) can produce a neurologic
injury with many physiological, psychological, and social rami-
fications (1). It has been shown that the two separate compo-
nents, the primary and secondary injuries, were previously
combined and were collectively thought to produce neuro-
logic damage in an acute spinal cord injury (2). The primary
mediator of a spinal cord injury is the actual mechanical tissue
disruption, which is a passive process that occurs immediately
after the trauma. A secondary injury cascade follows the initial
injury and appears to be mediated by cellular and molecular
processes that are working through complex mechanisms (3, 4).
The treatment with high doses of methylprednisolone (MP)
is a successful intervention of secondary spinal cord damage
(5). A significant improvement in neurological recovery was
found in humans with a SCI when a high-dose of MP was
administered within 8 hr after the trauma. A MP treatment,
that started later than 8 hr after the injury, had no beneficial
effects. Thus, it has been proposed that the dose and time of
MP administration are important factors in the treatment of
an acute SCI (6). 
However, conflicting results have also been reported. For
example, Ross and Tator (7) and Ross et al. (8) failed to demon-
strate the beneficial effects of a high-dose of MP on the post-
traumatic spinal cord blood flow and evoked potentials in a
rat model of spinal cord injury in the acute stage. Koyanagi
and Tator (9) found that none of the doses of MP ranging from
30 to 240 mg/kg improved post-traumatic spinal cord blood
flow. In both treatment groups, the somatosensory evoked
potentials, the cerebellar evoked potentials, and the posteri-
or fossa evoked potentials completely disappeared after the
injury and did not recover (at 3.5 hr). This indicates that a
single huge dose of MP had no beneficial effects on the trau-
matized rat spinal cord in the acute stage.
Therefore, it is not clear whether MP has any beneficial
effects on functional recovery after acute SCI. The present
study was conducted to observe functional recovery from the
behavioral deficits and electrophysiological abnormalities
following MP treatment in the spinal cords of rats subjected
to a traumatic contusion injury.
MATERIALS AND METHODS
Subjects
Male adult Sprague-Dawley rats (300-350 g) were used in
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Effects of Methylprednisolone on the Neural Conduction of the Motor
Evoked Potentials in Spinal Cord Injured Rats
Methylprednisolone (MP), a glucocorticoid steroid, has an anti-inflammatory action
and seems to inhibit the formation of oxygen free radicals produced during lipid
peroxidation in a spinal cord injury (SCI). However, the effects of MP on the func-
tional recovery after a SCI is controversial. The present study was conducted to
determine the effects of MP on the recovery of neural conduction following a SCI.
A SCI was produced using the NYU spinal cord impactor. A behavioral test was
conducted to measure neurological disorders, and motor evoked potentials (MEPs)
were recorded. According to the behavioral test, using BBB locomotor scaling,
MP-treated animals showed improved functional recoveries when compared to
saline-treated animals. MEP latencies in the MP-treated group were shortened
when compared to those in the control group. Peak amplitudes of MEPs were
larger in the MP-treated group than those in the control group. The thresholds of
MEPs tended to be lower in the MP-treated group than those in the control group.
These results suggest that MP may improve functional recovery after a SCI. 
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a series of studies. The rats were housed two per cage, exposed
to a 12 hr light/dark cycle, and had free access to food and
water. Experiments were carried out in accordance with the
NIH guidelines from the U.S.A. regarding the care and use
of animals for experimental procedures. All of the procedures
used in this experiment were approved by the Committee
for Animal Experiments in the Yonsei University College of
Medicine.
Surgical procedures for spinal cord injury
Spinal cord contusion surgeries were performed under pen-
tobarbital sodium (Entovar�, 50-70 mg/kg, i.p.) anesthesia
and prophylactic administration of gentamycin sulfate (1 mg/
kg). The thoracic area was shaved and prodine and alcohol
were applied to the skin. During surgery, the rat’s body tem-
perature was maintained at 37℃using a homeothermic feed-
back controlled heating pad. An incision was extended from
the mid to low thoracic regions. A laminectomy of T9 exposed
the spinal cord. For the contusion injuries, spinal clamps were
attached to the T7 and T12 spinous processes, a transducer
was placed over the transverse process of T10, and the impact
rod was centered above T9. The rod was slowly lowered until
it contacted the dura, which was determined by the comple-
tion of the circuit that activated a tone. The cord was then
contused with the NYU weight-drop device. 
Immediately after surgery, all rats were maintained in an
incubator until thermoregulation was reestablished. Postop-
erative nursing care included bladder expression two times
per day. 
Administration of methylprednisolone
After the injury, the rats were randomly assigned to two
groups and received an intravenous bolus injection of either
MP or physiological saline. The injection volume of the saline
and MP was 0.3 mL and the bolus was administered by hand
injection for over 1 min. MP (30 mg/kg) or saline was admin-
istered through the tail vein 15 min after the SCI.
Behavioral testing
This study followed the open field training and testing pro-
cedures previously described as the BBB locomotor rating
scale (10). Fourteen rats were trained preoperatively to move
in an open field which was a molded-plastic circular enclo-
sure with a smooth nonslip floor (90 cm diameter; 21 cm
wall height). The rats were gently adapted to the open field
for a short period of time. Once a rat walked continuously
in the open field, two examiners conducted a 5 min, preop-
erative testing session on each leg using the BBB locomotor
rating scale. Postoperative (p.o.) open field testing occurred
at least once a week from 1 day p.o. to 8 weeks p.o. for all
animals.
Motor evoked potential recording
Fifty-eight Sprague-Dawely rats were anesthetized with
pentobarbital given by an intraperitoneal injection (50 mg/kg).
Each animal was also given atropine sulfate (0.8 mg/kg) to
reduce tracheal secretions. Using a surgical microscope, the
right femoral artery and vein were catheterized and the tra-
chea was intubated. Pancuronium bromide (0.4 mL) was then
perfused through the femoral vein to induce muscle relax-
ation. Each rat was then artificially respired using a small ani-
mal respirator (Harvard Apparatus, South Natik, MA, U.S.A.)
and expiratory CO2 was maintained within the physiologi-
cal range using a capnometer (Model 2200, Traverse Medi-
cal Monitors, Saline, Michigan, U.S.A.). Each animal was then
placed on the stereotaxic device (Narishige Scientific Instru-
ment Laboratory, Setagaya-Ku, Tokyo, Japan) and the rectal
temperature was maintained between 36.5-37.5℃ using a
feedback controlled heating blanket (Harvard Apparatus,
South Natik, MA, U.S.A.). 
To stimulate motor cortex, a metal electrode (NE-120,
Rhodes Medical Instruments, Inc., distributed by David Kopf
Instruments, Tujunga, California, U.S.A.) which was origi-
nally designed for recording the sensory evoked potentials
in the cerebral cortex was used. The pointed tip of the elec-
trode, with a 0.5 mm long exposed area, was inserted into
the cerebral cortex perpendicular to the cortical surface. This
enabled gentle contact of the round flat surface with the cor-
tical surface. During cortical stimulation, the round area of
the electrode was the anode and the pointed tip was the cath-
ode. This electrode was designed to keep the cathode and the
anode close together in order to prevent current spread. In
addition, there was also a large enough surface for the activa-
tion of a large number of pyramidal neurons with a low inten-
sity electrical current. Furthermore, the direction of the cur-
rent flow was designed to be the same as the projection of the
pyramidal cell bodies. A single square pulse (0.1 msec dura-
tion) of electrical stimulus was delivered by a stimulus iso-
lator (A365D or A365, World Precision Instruments, Inc.,
New Heaven, Connecticut, U.S.A.), which was driven by a
pulse generator (Pulsemaster A300, World Precision Instru-
ments, Inc., New Heaven, Connecticut, U.S.A.). 
A laminectomy was performed at L1 of the spinal cord of
each rat for the placement of the epidural recording electrodes.
The shape and specifications of the recording electrodes were
the same as those of the stimulating elecrodes. Following the
laminectomy, the electrode was inserted into the contralat-
eral gray matter at L1 of the spinal cord. The pointed tip of
the electrode was used for activation and the rounded part
of the electrode was used as a reference electrode. The analog
signals of the evoked potential were amplified (AC amplifier,
Model RPS 107, Grass Instrument Co., W. Warwick, RI,
U.S.A.), filtered (bandpass 300-1,000 Hz), and averaged on
an IBM-compatible personal computer system equipped with
Spike 2 software (CED, Cambridge, U.K.). Each MEP con-134 B.H. Lee, K.H. Lee, D.H. Yoon, et al.
sisted of an average of 100-300 single sweep epochs. In order
to minimize the effect of the anesthetic on the MEP, record-
ing commenced at least 20 min after the injection of Entobar.
The threshold of the electrical stimulation was first deter-
mined in each experiment. The effect of the stimulation inten-
sity was analyzed on the wave form and latencies.
Statistical analysis
Data were expressed as mean±s.e.m. Differences between
the MP- and saline-treated groups at each post-operative time
point in the behavioral data were analyzed by Student’s t-
test. Differences between the MP- and saline-treated groups
at 2, 4, and 6 weeks p.o. in the electrophysiological data were
analyzed by the t-test. Statistical significance was inferred at
p<0.05.
RESULTS
Behavioral assessment
All of the animals showed a score of 21 before the SCI. After
the SCI, the animals seldom moved their hindlimbs. Fig. 1
shows the changes in locomotor deficits after the SCI. Behav-
ioral scores were measured by BBB methods. Data were ex-
pressed as mean±s.e.m. As shown in Fig. 1, BBB scores
decreased after the injury but then they slowly and gradual-
ly increased. When MP was administered (n=6), locomotor
behavior was enhanced when compared to the saline-treated
control group (n=8). An asterisk indicates a significant dif-
ference between the MP- and saline-treated groups at each
post-operative time point (p<0.05).
Motor evoked potentials
The MEP was recorded using a special disk electrode in
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Fig. 1. Changes in locomotor deficits after a spinal cord injury. Behavioral scores were measured by the BBB methods. The BBB scores
decrease after an injury and slowly and gradually increase. Intraperitoneally injected MP promoted a behavioral recovery following a SCI
when compared to the saline-treated control animals. Data were expressed as mean±s.e.m. Asterisks (*) indicate a significant differ-
ence between the MP- and saline-treated groups at each post-operative time point (p<0.05).
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Fig. 2. Representative motor evoked potentials (MEPs) recorded
in saline-treated SCI (upper left), MP-treated SCI (lower left), and
intact (right) animals. Note the different amplitude scales.
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L1 spinal cord after the hindlimb area of the motor cortex
was stimulated. When the hindlimb area of the motor cor-
tex was stimulated, a negative-positive-negative wave with
a short latency was observed at L1 spinal cord (an upward
deflection was designated as negative). 
MEPs obtained from the rats after a weight drop injury
consisted of only a few peaks above the detection level of 5
V. On the other hand, MEPs obtained from uninjured nor-
mal rats consisted of distinctive peaks with large amplitudes
(Fig. 2). After a spinal cord injury, the animals showed length-
ened MEP latencies and reduced amplitudes when compared
to the normal animals (Fig. 2). Fig. 2 shows representative
MEPs recorded in saline-treated SCI rats (upper left), MP-
treated SCI rats (lower left), and intact (right) rats. Different
amplitude scales were noted. Intraperitoneally injected MP
promoted an electrophysiological recovery following the SCI
when compared to the saline-treated control animals.
Fig. 3 shows changes in the latencies and amplitudes of
MEPs after a MP administration in the SCI animals. Data
were expressed as mean±s.e.m. Within the MEPs, the ini-
tial latencies (the rising phase of MEP) in the MP-treated
group [n=11 (2W); 9 (4W); 8 (6W)] were significantly short-
ened when compared to the saline-treated control group [n=11
(2W); 8 (4W); 11 (6W)] at 2, 4, and 6 weeks p.o. (p<0.05,
Fig. 3A). The latencies of N1 (the first negative deflection)
were not significantly different between the MP- and saline-
treated groups at 2, 4, and 6 weeks p.o. (p>0.05, Fig. 3B).
The latencies of P1 (the first positive deflection) were signifi-
cantly different between the MP- (n=9) and saline-treated
groups (n=8) at 4 weeks p.o. (p<0.05) but not at 2 and 6
weeks p.o. (p>0.05, Fig. 3C).
Fig. 4 shows the changes in the amplitudes of MEPs after
the MP administration in the SCI animals. Data were express-
ed as mean±s.e.m. Within the MEPs, the N1 amplitudes
in the MP-treated group (n=11) had significantly increased
when compared to the saline-treated control group (n=11) at
2 weeks p.o. (p<0.05, Fig. 4A) but not at 4 and 6 weeks p.o.
(p>0.05). Similarly, the P1 amplitudes in the MP-treated
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Fig. 3. Changes in latencies of MEPs after MP administration in
the SCI animals. (A) Comparison of the initial latencies (the rising
phase of MEPs) in the MP- and saline-treated groups at 2, 4, and
6 weeks p.o. (B) Comparison of the N1 (the first negative deflec-
tion) latencies in the MP- and saline-treated groups at 2, 4, and 6
weeks p.o. (C) Comparison of the P1 (the first positive deflection)
latencies in the MP- and saline-treated groups at 2, 4, and 6 weeks
p.o. Data were expressed as mean±s.e.m. Asterisks (*) indicate a
significant difference between the MP- and saline-treated groups
at each post-operative time point (p<0.05).
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group (n=11) had significantly increased when compared to
the saline-treated control group (n=11) at 2 weeks p.o. (p<
0.05) but not at 4 and 6 weeks p.o. (p>0.05, Fig. 4B).
DISCUSSION
Although axons in the peripheral nervous system have the
capacity to regrow after an injury (11, 12), injured central
nervous system axons fail to regenerate (13, 14). Similarly,
in the spinal cord, the final sequences of a SCI are related to
both the initial physical impact and the numerous secondary
injury factors occurring in and around the site of the prima-
ry damage over a period of time (days or months).
In the present study, behavioral motor deficits were observed
after a SCI. When the MEPs were measured, the latencies of
the MEPs were lengthened. These behavioral and electrophys-
iological deficits may have resulted from the primary physi-
cal insult as well as the secondary injury.
A common treatment for a SCI in human beings is the
administration of MP (5, 6). Several studies have shown that
MP recovers post-traumatic functional deficits in experimen-
tal SCIs using a weight drop in different species such as the
rat (15), cat (16, 17), and monkey (18). However, some stud-
ies have reported that MP is not effective for improving func-
tional recovery after different injury models such as the weight
drop (19, 20), clip compression (8, 21, 22), and heat injury
with a radiofrequency current (23), in different species such
as the dog (19), cat (20) and rat (8, 19, 21-23). In the pre-
sent study, we observed behavioral recovery after a MP injec-
tion using a weight drop model using the BBB test.
The effect of MP on evoked potentials after an experimen-
tal SCI has been examined by several studies. Two studies
(24, 25) have reported significant recovery of the somatosen-
sory evoked potentials (SSEPs) by MP, while others have shown
no improvement (7-9). Koyanagi and Tator (9) observed that
MP did not improve the SSEP, reflecting mainly the dorsal
column pathways. Furthermore, Ross and Tator (7) moni-
tored MEPs in clip compression-injured rats, but the MEPs
had not improved following an MP treatment. In the present
study, the latencies of MEPs were shortened and the ampli-
tudes were increased after an MP injection. Contrast to N1
or P1 latencies which were variable from stimulation to stim-
ulation, the initial latencies were measured constantly. The
initial latencies of MEPs were shortened after an MP injec-
tion at 2, 4, and 6 weeks p.o. On the contrary, we could not
observe any improvement in SSEPs (unpublished data). The
reason why MP improved MEP but not SSEP is not clear at
present. Most of ascending pathways including dorsal col-
umn might be injured too severely to be regenerated by con-
tusion injury but descending pathways might be affected
less to be regenerated. However, these electrophysiological
findings correspond to a behavioral phenomenon. Therefore,
MP was effective in both the behavioral and electrophysio-
logical functional recovery after a SCI.
One mechanism that explains the action of MP, is the bind-
ing of the glucocorticoid receptor, which mediates its anti-
inflammatory properties. MP inhibits the inflammatory pro-
cesses induced after a SCI (26). MP also inhibits phospholi-
pase A2 activity (27), which reduces production of the metabo-
lites of the arachidonic acid cascade (28) thereby reducing the
formation of free radicals (27, 28). MP also reduces the expres-
sion of the tumor necrosis factor by decreasing the activation
of NF- B, thereby diminishing the intensity and duration
Fig. 4. Changes in amplitudes of MEPs after the MP administration in the SCI animals. (A) Comparison of the N1 (the first negative deflec-
tion) amplitudes in the MP- and saline -treated groups at 2, 4, and 6 weeks p.o. (B) Comparison of the P1 (the first positive deflection) ampli-
tudes in the MP- and saline-treated groups at 2, 4, and 6 weeks p.o. Data were expressed as mean±s.e.m. Asterisks (*) indicate a sig-
nificant difference between the MP- and saline-treated groups at each post-operative time point (p<0.05).
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of the inflammatory response (29). Whereas these effects are
achieved with the administration of MP at a dose of 0.03
mg/kg (30), to be clinically effective after a SCI, MP must
be administered at the large dose of 30 mg/kg (31). At this
dose, MP exhibits antioxidant effects, which allow it to scav-
enge free radicals, thus decreasing the oxygen radical-induced
lipid peroxidation of cell membranes (32). According to Nash
et al. (33), MP was found to promote axonal regeneration and
improve functional recovery after a rat SCI when compared
to untreated rats. According to a recent report (34), however,
MP may depress the production of growth-promoting fac-
tors following acute SCI. Therefore, MP is regarded to have
multiple mechanisms for improving functional recovery after
a SCI.
At present, many therapies to promote neuronal regener-
ation after a SCI have been investigated, including the injec-
tion of chemicals like MP, surgery, cell therapy, etc. However,
it does not appear that any single therapy will solve all of
the problems associated with the lack of regeneration after a
SCI. It would be helpful to treat a SCI with a combination
of two or more effective therapies such as brain-derived neu-
rotrophic factor and MP (35).
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